U.S.-based IQ-AI has been awarded a European patent for an MRI processing protocol designed to reduce the volume of gadolinium contrast in perfusion exams.
Called "Multiparameter Perfusion Imaging with Leakage Correction," the patent applies to an MRI technique referred to loosely as "dual echo." The method simultaneously generates both dynamic contrast and dynamic contrast-enhanced permeability parameters using a single, more simplified MRI acquisition sequence.
The protocol eliminates the need to administer preload doses of gadolinium-based contrast agents (GBCA), which results in a 50% reduction in GBCA consumption for MRI perfusion data acquisition, according to the company.
The sequencing protocol is already patented in the U.S., the company said.